The body uses certain checkpoint proteins on cells to stop the immune system from attacking normal, healthy cells. Cancer cells sometimes use these checkpoints to keep from being attacked by the immune system. Immune checkpoint inhibitors are medicines (monoclonal antibodies) that block specific checkpoints. This helps the immune system recognize and attack the cancer cells.
When are immune checkpoint inhibitors used to treat prostate cancer?
Immune checkpoint inhibitors can be used in advanced prostate cancer cases, where the cancer:
- Begins to grow again after chemotherapy.
- Can't be treated with surgery.
- Comes back (recurs) after treatment.
- Spreads to other parts of the body (metastasizes).
How are immune checkpoint inhibitors used to treat prostate cancer?
There are two immune checkpoint inhibitor medicines used for prostate cancer.
- Pembrolizumab. This medicine may be used for people with prostate cancer cells that have any of these gene changes (mutations):
- Changes in the mismatch repair genes (MMR)
- Signs of microsatellite instability (MSI) in the tumor
- A high tumor mutational burden (TMB)
- Dostarlimab. This medicine may be an option for people with advanced prostate cancer that has DNA mismatch repair deficiency (dMMR).
Both of these medicines work by blocking a checkpoint protein called PD-1. PD-1 is found on immune cells called T cells. PD-1 normally helps stop the T cells from attacking healthy, noncancer cells in the body. Blocking this protein helps the immune system kill cancer cells.
How are immune checkpoint inhibitors given for prostate cancer?
These medicines are given by an I.V. (intravenous) infusion into your vein. This is done once every 2 or 3 weeks.